A Protocol for Assessment of Interventions Using a Computational Phenotype for Long COVID

    March 2026 in “ medRxiv ”
    Amitabh Amitabh Gunjan, Lawrence Huang, Anudeep Appe, Paul A. McKelvey, Heather A. Algren, Mark Berry, Essy Mozaffari, Bill Wright, Jennifer Hadlock, Jason D. Goldman
    Image of study
    TLDR Long COVID symptoms are common and the new method will help test if remdesivir reduces them.
    This study utilized electronic health records from a multistate healthcare system to assess the impact of remdesivir on Long COVID in patients hospitalized with acute COVID-19. The study included 45,540 COVID-19 patients and 409,186 non-COVID patients. Results showed that 38.0% of the COVID-19 group and 29.3% of the non-COVID group met the primary outcome of post-COVID conditions or secondary outcomes within 90 to 365 days post-admission. The weighted hazard ratio for the primary outcome was 1.37, indicating a higher risk in the COVID-19 group. Secondary outcomes strongly associated with COVID-19 included thromboembolism, hair loss, diabetes, obesity, and hypoxia. The study concludes that Long COVID manifestations are detectable in routine clinical diagnoses and that the computational phenotype developed will be used to evaluate the effectiveness of remdesivir in reducing Long COVID.
    Discuss this study in the Community →